Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-11-26
2000-04-04
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514261, 514262, 514266, 544254, 544255, 544256, 544257, 544262, 544266, 544267, 544268, 544269, 544278, 544279, 544280, 544286, A61K 31505, C07D23900, C07D47100, C07D48700
Patent
active
060462078
ABSTRACT:
The present invention relates to a compound of the formula and the pharmaceutically acceptable salts thereof wherein W is a bicyclic heterocyclic ring system. The compounds are .alpha.-1 adrenergic antagonists and are useful in the treatment of BPH; also disclosed are .alpha.-1 antagonist compositions and a method for antagonizing .alpha.-1 adrenoreceptors and treating BPH.
REFERENCES:
patent: 3888946 (1975-06-01), Pars et al.
patent: 4117140 (1978-09-01), Brown et al.
patent: 4385056 (1983-05-01), Loozen
patent: 5387591 (1995-02-01), Lavielle et al.
patent: 5597823 (1997-01-01), Meyer et al.
patent: 5663191 (1997-09-01), Lavielle et al.
Pars, H. G., et al., "Drugs Derived from Cannabinoids. 1 Nitrogen Analogs. Benzopyridines and Benzopyranopyrroles", Journal of Medicinal Chemistry, 19(4):445-453 (1976).
Caine, et al., "Adrenergic and Cholinergic Receptors in the Human Prostate, Prostatic Capsule and Bladder Neck", British Journal of Urology, 47:193-202 (1975).
Chapple, "Medical treatment for benigh prostatic hyperplasia", BMJ, 1198-1199 (1992).
Chapple, et al., "Characterisation of Human Prostatic Andrenoceptors using Pharmacology receptor Binding and Localisation", British Journal of Urology, 63:487-496 (1989).
Chapple, et al., "A Twelve-Week Placebo-Controlled Study of Prazosin in the Treatment of Prostatic Obstruction", Urol Int, 45(1):47-55 (1990).
Chow, et al., "Multicentre Controlled Trial of Indoramin in the Symptomatic Relief of Benigh Prostatic Hypertrophy", British Journal of Urology, 65:36-38 (1990).
Gittes, et al., "Female Urethral Syndrome A Female Prostatitis?", WJM, 164(5):435-438 (1996).
Hoffman, et al., "Alpha Adrenergic Receptor Subtypes in Rabbit Uterus: Mediation of Myometrial Contraction and Regulation by Estrogens", The Journal of Pharmacology and Experimental Therapeutics, 219(2):290-295 (1981).
Janknegt, et al., "Efficacy and Safety of the Alpha-1 Blocker Doxazosin in the Treatment of Benigh Prostatic Hyperplasia", Eur Urol, 24:319-326 (1993).
Lepor, "Alpha Blockade for the Treatment of Benigh Prostatic Hyperplasia", Urologic Clinics of North America, 22(2):375-386 (1995).
Miller, et al., "Uterine response to nerve stimulation; relation to hormonal status and catecholamines", American Journal of Physiology, 209:859-863 (1965).
Roberts, et al., Regulation of Myometrial Adrenoreceptors and Adrenergic Response by Sex Steroids:, Molecular Pharmacology, 20:52-58 (1981).
Rosier, et al., "Is Detrusor Instability in Elderly Males Related to the Grade of Obstruction?", Neurourology and Urodynamics, 14:625-633 (1965).
Thien, et al., "Urinary incontinence caused by prazosin", British Medical Journal, 622-623 (1978).
Altenbach Robert J.
Basha Fatima Z.
Carroll William A.
Drizin Irene
Haight Anthony R.
Kifle Bruck
Raymond Richard L.
Ward Michael J.
LandOfFree
Benzopyranopyrrole and benzopyranopyridine .alpha.-1 adrenergic does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzopyranopyrrole and benzopyranopyridine .alpha.-1 adrenergic , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzopyranopyrrole and benzopyranopyridine .alpha.-1 adrenergic will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-365523